N/A N=31 The Effectiveness of Biofeedback for Individuals With Long-term Post-concussive Symptoms
Post-Concussion Syndrome
Primary: Change In SDNN — 43.; 21.87; 19.4 ms
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=15 Fatiguing Arm Exercise Following Stroke
Stroke
Primary: Short Intracortical Inhibition (SICI) — 0.83; 1.14; 0.89; 0.88 SICI ratio — p=0.15
Phase 2 N=41 A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia
Alzheimer's Disease
Primary: Donepezil Maximum Tolerated Dose (MTD) — 0; 0; 0; 0 Participants
Phase 3 N=1,351 Stepping Stones and Creating Futures Intervention Trial
IPV · Sexual Violence
Primary: Any Past Year Physical Intimate Partner Violence Perpetration (Men) and Experience (Women) — 134; 86; 155; 118 Participants — p==0.686
Phase 4 N=225 Adult Oral Ibuprofen Study for ED Pain Patients
Pain, Acute
Primary: Pain Reduction at 60 Minutes From Baseline of the 3 Oral Ibuprofen Groups — -2.12; -1.85; -1.96 units on a scale
N/A N=120 RCT(Randomized Clinical Trial ) of Antibiotic Therapy in Chronic Endometritis
Chronic Endometritis
Primary: The Conversion Rate of CE (From Positive to Negative) — 89.8; 12.7 Percentage of participants
N/A N=32 Neuromuscular Blocking Agents in the Elderly
Elective Surgery
Primary: Onset Time — 135; 90 seconds — p=<0.001
Phase 1 N=35 A MAD Study of TT301/MW189 in Healthy Volunteers
Healthy Adult Volunteers
Primary: Serious Adverse Events — 0; 0; 0; 0 Participants
N/A N=20 Evaluation of Intensive Language Therapy
Parkinson's Disease
Primary: Velocity in Gait — 1.2; 1.2; 1.2; .8 meter per second — p=.05
Phase 1 N=37 Evaluate the PK, Safety, Tolerability of Ferric Maltol at 3 Dosage Levels in Paediatric Subjects With Iron Deficiency
Iron Deficiency, Anaemia in Children · Iron-Deficiency
Primary: Maximum Plasma Concentration [Cmax] of Maltol Glucuronide on Day 1 — 2.4518; 1.1632; 0.5299 mg/L
N/A N=239 Clinical Trial Comparing Decompression With and Without Coflex™ Interlaminar Technology Treating Lumbar Spinal Stenosis
Spinal Stenosis
Primary: Change in ODI From Baseline to 24 Months — -19.0; -22.5 percentage points
Phase 3 N=1,009 A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea
Rosacea
Primary: Percent Change From Baseline to Week 12 in the Inflammatory (Papules and Pustules) Lesion Counts. — -66.96; -68.62; -38.64 Percent change in lesion counts
N/A N=23 HALO: A Single Arm Prospective Investigation of the SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve
Mitral Valve Disease · Damaged Mitral Valve · Malfunctioning Mitral Heart Valve
Primary: Primary Effectiveness Endpoint: Kaplan-Meier Percentage of Participants Who Remained Alive or Had Valve Explanted Due to Anatomical Growth — 71.0 percentage of…
N/A N=63 Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma
Diffuse Large B-cell Lymphoma
Primary: Number of Participants With Local Control — 61 Participants
Phase 3 N=630 Clinical Endpoint Study of Ivermectin 1% Cream
Moderate to Severe Papulopustular Rosacea
Primary: Percent Change From Baseline to Week 12 in the Number of Inflamed (Papules/Pustules) Lesions of Rosacea. — -64.87; -64.87; -55.04 percentage of change from baseline…